MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2026 International Congress » Parkinson's disease: Biomarkers (non-Neuroimaging)

Meeting: 2026 International Congress

A composite oculomotor biomarker for differentiating Parkinson’s disease from multiple system atrophy

M. Wójcik-Pędziwiatr, D. Hemmerling, J. Sikora, J. Stępień, W. Szecówka, M. Baran, M. Rudzińska-Bar (Kraków, Poland)

A Machine Learning-Based Approach to Identify Responders to Electrosonic Brain Stimulation in Parkinson’s Disease

L. Dipietro, U. Eden, S. Elkin-Frankston, M. El-Hagrassy, D. Doruk Camsari, C. Ramos-Estebanez, F. Fregni, T. Wagner (Cambridge, USA)

A Pilot Study of Phosphorylated Alpha-Synuclein Detection and Quantitation from Routine Colonic Biopsies in Patients with Parkinson’s disease

T. Levine, R. Freeman, B. Bellaire, J. Parent, S. Marcotte, M. Duval, C. Gibbons (Boston, USA)

A Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Fluid Biomarkers in Parkinson’s Disease

STT. Nguyen, J. Ruiz Tejeda, D. Tran, R. Rajmohan, N. Phielipp (Irvine, USA)

Age-Dependent Peripheral Dissemination of α-Synuclein Seeds: Mechanistic Basis for Blood-Based Early Detection of Parkinson’s Disease

K. Kuang (Guangzhou, China)

AI-based Progression and Medication Response Prediction in Parkinson’s Disease: the AI-PMP Study Protocol

N. Del Campo, S. Hadjidimitriou, C. Chatzichristos, O. Sánchez-Soliño, M. Kurtis, M. Almarcha-Menargues, B. Falkenburger, A. Saad, T. Strypsteen, C. Kyproula, P. Chairta, T. Scott Duncan, I. Gerasimou, A. Drif, N. Schnalke, E. de Pablo-Fernández, M. de Vos, O. Rascol, L. Hadjileontiadis, M. Fabbri (Toulouse, France)

Alpha-synuclein Seed Amplification Assay Set Up: Quality Control Using Standards and Controls

B. Huxford, A. Noyce (London, United Kingdom)

Amyloid status as a moderator of the association between physical activity and progression of Parkinson’s disease

MJ. Lee, K. Pak, M. Kim, JH. Lee (Busan, Republic of Korea)

Assessing the Effects of Anti-Parkinsonian Medication Using Wearable Sensor-Derived Kinematic Data and Machine Learning

A. Siekmann, C. Sotirakis, J. Huxley, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

Association of Neurofilament Light Chain with Substantia Nigra Degeneration in Parkinson’s Disease

WJ. Wu, WQ. Jiang, QY. Zheng, L. Luo, Y. Zhang, XY. Zhang, ZM. Dong, ZY. Yu, T. Wu, XJ. Dai, DL. Zhang (Beijing, China)

Association of Serum Linoleic Acid-containing Plasmalogens With Parkinson’s Disease: the PPMI Study

D. Wang, Y. Liu (Jinan, China)

Associations Between Saccadic and Motoric Symptoms in Parkinson’s Disease

M. Gibbs, A. D'Souza, C. Sotirakis, T. Crawford, C. Antoniades (Oxford, United Kingdom)

Associations of Accelerated Biological Aging With Parkinson’s Disease

L. Luo, M. Wang, T. Ai, Q. Zheng, W. Wu, Y. Wang, T. Wu, Y. Pan, D. Zhang (Beijing, China)

Automated differential diagnosis of Parkinson’s disease and Parkinson-like disorders via motion capture analysis

W. Sako, M. Osawa, T. Hara, T. Iguchi, H. Haginiwa, S. Haji, T. Hatano, N. Hattori (Tokyo, Japan)

Baseline plasma neurofilament light and phosphorylated tau 181 levels predict longitudinal cognitive decline in APOE4 and long SNCA Rep1 carriers in Parkinson’s disease

S. Ng, J. Tan, E. Saffari, E. Ng, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan, A. Ng (Singapore, Singapore)

Beta and Gamma Local Field Potentials in Chronic Deep Brain Stimulation for Parkinson’s Disease: Programming Implications from a Systematic Review

KS. Thu Aung, S. Lane, J. Osman-Farah, A. Macerollo (Liverpool, United Kingdom)

Beyond Freezing of Gait Episodes in Parkinson’s Disease: Intercritical Kinematic Gait Pattern Matters.

G. de Biasi, F. Di Filippo, L. Santos, C. Ricciardi, M. Russo, N. Pisani, MC. Calabrese, M. Romano, M. Picillo, R. Erro, MT. Pellecchia, P. Barone, M. Amboni (Salerno, Italy)

Beyond the Spinal Tap: Diagnostic Accuracy of Alpha-Synuclein Seeding Amplification Assays (SAA) in Cutaneous and Ocular Biofluids – A Comparative Diagnostic Accuracy Review

F. Al-Zaidi (Almaty, Kazakhstan)

Biofluid Markers in Parkinson’s Patients and Correlation with Cognitive Profile

T. Yamasaki, R. Vivanco, J. Johnson, S. Ali, F. Schmitt, A. Glueck, A. Jacob, S. Hulou, M. Khashimov, K. Tackett, C. Logan, J. Stegemann, E. Song, E. Ostrakhovitch (Lexington, USA)

Biological Predictors of Clinical Domains in Isolated REM Sleep Behavior Disorder with and without Synucleinopathy and Dopamine Dysfunction

D. Weintraub (Philadelphia, USA)

Brain-Derived Neurotrophic Factor as a Biomarker of Depression in Parkinson’s Disease

IH. Kwak, YE. Kim, HI. Ma, JK. Yu, DG. Ko, JJ. Lee, HD. Nguyen, HBT. Tran, HJ. Choi, SJ. Song (Anyang, Republic of Korea)

Burst versus Conventional Deep Brain Stimulation Engage Distinct Cortico-Subthalamic Circuit Dynamics in Parkinson’s Disease

T. Sil, L. Lange, L. Juarez-Paz, B. Duarte, H. Bokil, M. Reich, M. Muthuraman, J. Volkmann (Wuerzburg, Germany)

Cerebrospinal Fluid Markers are associated with Cognitive Decline in GBA1-associated Parkinson’s Disease

M. Bode, C. Schulte, S. Becker, I. Wurster, B. Roeben, S. Lerche, W. Poewe, K. Brockmann, I. Liepelt-Scarfone (Tübingen, Germany)

Characterising immune changes in the nose in Parkinson’s disease

C. Tournerie, B. Patel, M. Camacho, A. Friend, M. Schaepers, W. Woods, C. Williams-Gray (Cambridge, United Kingdom)

Characteristics of Cortical Beta Bursts in Parkinson’s disease

L. Witt, L. Chen, S. He, A. Pogosyan, L. Timmermann, H. Tan, D. Pedrosa, P. Loehrer (Marburg, Germany)

Clinical and Patient-Reported Outcomes in Patients With and Without Severe Bradykinesia According to Sensor Measurements

D. von Below, S. Wallerstedt, F. Bergquist (Gothenburg, Sweden)

Clinical Relevance of Oral Health Assessment in Parkinson’s Disease Monitoring

R. Naqvi, V. Ha, S. Elshourbagy, A. Valverde, S. Tomar, J. Schwartz, A. Naqvi, P. Engen, M. Shaikh, C. Neumann, M. Villanueva, D. Sanchez-Bass, L. Dibenedetto, R. Voigt, C. Goetz, A. Keshavarzian (Chicago, USA)

Decoding Parkinson’s Disease Metabolic Landscape: Targeted 4D-Metabolomics of Urinary Amine-Phenol Submetabolomes for Specific Signature Identification and Biomarker Discovery

Y. Zhang, X. Huang, Y. Zhou, C. Shen, L. Cao (Shanghai, China)

Delineating Therapeutic and Non-therapeutic Neural Signatures of Deep Brain Stimulation

T. Sil, P. Navratil, G. Abbas, J. Volkmann, M. Muthuraman, M. Reich, R. Peach (Wuerzburg, Germany)

Detection of α-synuclein seeds in skin samples from PPMI participants

Y. Ma, C. Farris, R. Johnson, S. Rosete-Gonzalez, D. Murphy, T. Foroud, L. Concha (San Diego, USA)

Developing non-invasive EEG biomarkers for Parkinson’s disease using concurrent subthalamic nucleus/cortical recording as ground truth.

MI. de Bartolo, G. Leodori, M. Mancuso, F. Marchet, F. Aiello, A. Conte, A. Berardelli, D. Belvisi, M. Marano, G. Fabbrini (Rome, Italy)

Dietary and Environmental Risk Factors of Parkinson’s Disease: An Integrated Network Pharmacology Approach

D. Ghosh, P. Basu, S. Mondal, S. Dey, S. Pal (Kolkata, India)

Digital Handwriting Analysis: A Useful Tool to Quantify Acute Dopaminergic Response in Parkinson’s Disease

L. Díaz-Feliz, M. Faundez-Zanuy, A. Gennari, P. Sanz-Cartagena, J. Arbelo-Gonzalez, M. García-Cabezas, P. García-Ruiz (Las Palmas GC, Spain)

Digital Mobility Outcomes for Modelling Self-Perceived Gait Security in People with Parkinsonian Disorders

F. Boschi, S. Sapienza, M. Giraitis, G. Zelimkhanov, F. Terranova, H. Gaßner, J. Goncalves, J. Klucken (Belvaux, Luxembourg)

Digital Respiratory Biomarkers as Early Indicators of Dysphagia and Aspiration Risk in Parkinsons Disease A Systematic Review

M. Kakde, S. Kakde, S. Kakade (Pune, India)

Digital Speech Biomarkers Reveal Speech Changes in Physiological Aging and Parkinson’s Disease

L. Novakova, K. Novotny, D. Kovac, J. Mekyska, I. Rektorova (Brno, Czech Republic)

Disentangling Disease- and Medication-Associated Gut Microbiome Signatures in Parkinson’s Disease

MG. Choi, SY. Jo, JY. Lee, HN. Im, GY. Lee, SJ. Chung (Seoul, Republic of Korea)

Distinct HD-EEG Functional Connectivity Patterns in Early-Onset Parkinson’s Disease

C. Simonetta, V. Ferrari, D. Mascioli, F. Carparelli, S. Bagetta, J. Bissacco, M. Pierantozzi, M. Mancini, V. Buttarazzi, K. Meksi, A. Stefani, D. Centonze, T. Schirinzi, M. Conti (Rome, Italy)

Do Digital Mobility Outcomes Differ Across Clinically Defined NSD-ISS Stages in Parkinson’s Disease?

P. Tait, L. Alcock, C. Schlenstedt, C. Caroll, C. Becker, J. Buekers, B. Caulfield, A. Cereatti, S. Del-Din, L. Delgado-Ortiz, J. Garcia-Aymerich, S. Koch, P. Ginis, H. Gassner, A. Nieuwboer, J. Hausdorf, A. Mirelman, L. Rochester, W. Maetzler, A. Yarnall (Newcastle upon Tyne, United Kingdom)

Dual-Task Cost Assessment in Parkinson’s Disease: A Literature Review of Clinical Applications and Measurement Approaches

C. Balasubramanian, Z. Board, J. Thomas, H. Malik, S. Bagdadi, I. Khan, K. Mangipudi (Jacksonville, USA)

Dysregulation of the Intestinal Macrophage CXCL8/CXCR2 Axis and Its Role in α-Synuclein Clearance

H. Hu, T. Tang, W. Wang (Shanghai, China)

EEG-based Functional Connectivity Reveals a Genotype-Specific Network Signature in GBA-Associated Parkinson’s Disease

M. Conti, V. D'Onofrio, M. Avenali, L. Lorenzon, L. Grassi, M. Ginevrino, L. Salviati, M. Terzaghi, M. Carecchio, A. Stefani, EM. Valente, A. Antonini, A. Guerra (Rome, Italy)

Elevated Myeloperoxidase Levels and Activity as Potential Biomarkers for Parkinson’s Disease: A Systematic Review and Meta-Analysis

S. Karki, A. Parajuli (Kathmandu, Nepal)

Enteric Alpha-Synuclein Pathology in Early-Onset Parkinson’s Disease and an Incidental Case in Spinocerebellar Ataxia Type 6

C. Shin, SI. Kim, SH. Park, JM. Kim, JY. Lee, SJ. Chung, JW. Kim, TB. Ahn, KW. Park, JH. Shin, HY. Lee, SH. Kong, YS. Suh, HJ. Kim, B. Jeon (Seongnam-si, Republic of Korea)

Event-Locked Characterization of Movement-Related Beta Modulation using Synchronized Local Field Potentials and Video-Based Kinematics

D. Hubers, BJ. Keulen, A. Vander Weide, BCM. van Wijk, PR. Schuurman, RMA. de Bie, M. Beudel (Amsterdam, Netherlands)

Exploring the Impact of Parameter Selection on Digital Sleep Outcomes in Parkinson’s Disease: Results from the IDEA-FAST Study

M. Sedghi, S. Del Din, W-F. Ng, W. Maetzler, NV. Manyakov, S. Avey, R. Göder, C. Pinaud, M. Chatterjee, RZ. Ur Rehman, JP. Taylor, L. Alcock, RA. Lawson (Newcastle upon Tyne, United Kingdom)

Fibrinogen and CFAH as putative biomarkers for Parkinson’s disease

P. Alladi, S. Choudhury, R. Bhavani, NC. Krithika, K. Krishnakumari, H. Jyothi, A. Mahadevan, P. Pal, V. Holla, S. Hegde, N. Kamble, R. Yadav (Bengaluru, India)

Gait Kinematics as Biomarkers of Preclinical Parkinson’s Disease: A Systematic Review of Sensor-Based Studies

K. Makhoul, N. Elayan, K. Fisher, R. Ramdhani (New York, USA)

Gut Barrier Failure In Parkinson Disease: Reduced Colonic Resilience In Moderate Disease And Spontaneous Pan-Intestinal Leak In Severe Disease

M. Abdel-Mohsen, M. Shaikh, L. Zhang, P. Engen, C. Neumann, M. Villanueva, D. Sanchez-Bass, L. Dibenedetto, S. Luo, B. Killinger, C. Soto, S. Green, L. Lagorio, R. Voigt, A. Sharma, C. Goetz, A. Keshavarzian (Chicago, USA)

Heart Rate Variability in Early Parkinson’s Disease

SJ. Chung, D. Kang, J. Lee, PH. Lee, YJ. Kim, YH. Sohn (Seoul, Republic of Korea)

Hepatic Biomarker Profile Across Parkinson’s Disease Severity Stages in a Peruvian Cohort

J. Moya-Salazar, F. Peralta-Hilario, I. Pasco, B. Cañari, A. Sobrino-Galindo, H. Contreras-Pulache (Chiclayo, Peru)

High-dimensional proteomic profiling in plasma and CSF identifies molecular signatures in Parkinson’s disease

S. Rota, B. Batzu, M. Veronese, J. Shubert, A. Heslegrave, B. Fernandes Gomes, A. Reith, C. Parker, S. Lee, N. Barwick, S. Williams (London, United Kingdom)

Identification of Alpha-synuclein Pathology in Idiopathic Rapid Eye Movement Sleep Disorder Participants by Seed Amplification Assay

C. Farris, S. Weber, Y. Ma, M. Starke, B. Mollenhauer, L. Concha (San Diego, USA)

Identification of Discriminative Odorants for Parkinson’s Disease and Their Clinical Correlates: A Population-Specific Short-Form Approach

YH. Lin, TC. Fang, MH. Chang, YJ. Guo (Taichung, Taiwan)

Identifying Parkinson’s Disease Subtypes Using Fluid Biomarkers Clustering in the PPMI Cohort

C. Mcintyre, N. Maki, J. Li, J. Ruiz Tejeda, R. Rajmohan, N. Phielipp (Chicago, USA)

Impact of Symptom-Specific Odorants on the Diagnostic Accuracy of Brief Olfactory Tests in Parkinson’s Disease

TC. Fang, YH. Lin, MH. Chang, YJ. Guo (Taichung, Taiwan)

IMU Insole-Derived Gait Digital Biomarkers in idiopathic RBD and Parkinson Disease

JH. Jung, M. Son, J. Jeon, SY. Kang, PH. Lee, SJ. Kim (Busan, Republic of Korea)

Investigating Plasma SIRT3 and SYT11 as Potential Indicators in Parkinson’s Disease: A Preliminary Exploratory Study

Y. Deng, H. Cao, Q. Qu, Y. Wang (Xi'an, Shaanxi Province, China)

Isolated REM Sleep Behavior Disorder is Associated with Altered Nocturnal Skin Temperature Dynamics

I. Roura, J. Pardo, C. Martín-Barceló, L. Pacheco-Jaime, C. Garcia-Vicente, C. Falcon, JA. Madrid, A. Rol, R. Sala-Llonch, M. Serradell, C. Pont-Sunyer, C. Gaig, G. Mayà, A. Montini, A. Adan, C. Junque, A. Iranzo, B. Segura (Barcelona, Spain)

Kinetic Features of Alpha-synuclein Positivity in CSF Seed Amplification in Parkinson’s Disease: an Exploratory Cross-cohort Analysis

A. Wen, R. Rajmohan (Irvine, USA)

Large-Scale Shotgun Mass Spectrometry in Parkinson’s Disease Plasma Identifies Novel Biomarker Candidates

S. Khosousi, L. Velayudhan, X. Yang, S. Lynham, P. Andrén, A. Hye, P. Svenningsson (London, United Kingdom)

Long-term outcomes and real-world implementation of adaptive deep brain stimulation in Parkinson’s disease

V. Witzig, J. Busch, J. Kaplan, J. Behnke, L. Drescher, J. Habets, A. Kühn (Berlin, Germany)

Longitudinal Association Between Baseline CSF GFAP Levels and Clinical Progression in Parkinson’s Disease A PPMI Study

Z. Huseynli (Istanbul, Turkey)

Longitudinal Changes and Clinical utility of the Neurological Pupillary Index in De Novo Parkinson’s Disease

JSL. Lee, SY. You (Daegu, Republic of Korea)

Longitudinal Decline of Alanine Aminotransferase Activity in Parkinson’s Disease and Its Association with Disease Duration

G. Maayan Eshed, M. Shemesh, N. Omer, R. Alcalay, M. Gana-Weisz, O. Goldstein, A. Mirelman, A. Thaler (Tel Aviv, Israel)

Longitudinal α-synuclein Seed Amplification Assay Analysis of PPMI Participants

L. Concha-Marambio, C. Gochanour, J. Yin, C. Farris, Y. Ma, D. Lafontant, T. Simuni, K. Marek, T. Tropea, D. Coughlin (Iowa, USA)

Markerless Kinematics of Levodopa Response During Activities of Daily Living in Parkinson’s Disease

J. Yun, S. Haar (London, United Kingdom)

Metabolic Frailty Shows Limited Predictive Insights into Motor Severity and Progression in Parkinson’s Disease Beyond Lifestyle and Cardiometabolic Determinants

M. Mijnsbergen, R. Weijer, L. Kuijer, J. van Hilten, J. Deelen, D. Hepp (Leiden, Netherlands)

Metabolomic profile as a biomarker of non-motor symptoms severity in patients with Parkinson’s disease

K. Aguiar, A. Carioca, I. Santos, F. Rolim, A. Ferreira Gomes, AS. Lima Verde, C. Figueiredo, F. Carvalho (Fortaleza, Brazil)

Microsaccade Alterations and Clinical Correlates in Parkinson’s Disease

T. Soumala, P. Tsitsi, Y. Wang, M. Nilsson, P. Svenningsson, I. Markaki (Stockholm, Sweden)

Mild Motor Impairments in Rapid Eye Movement Behavior Disorder: Tremor and Bradykinesia

JH. Lee, ER. Tobin, EA. Christou, XY. Lou, M. Louis, LH. Le, MF. Presti, MS. Jaffee, DE. Vaillancourt (Gainesville, USA)

Monitoring of Motor Complications with Wearable Technology in Parkinson’s Patients Considered for Deep Brain Stimulation

JC. Romero-Fábrega, L. Muñoz Delgado, E. Muñoz Campo, F. Carrillo García, B. Fernández-Rodríguez, R. Rashid-López, R. Espinosa-Rosso, L. García-Trujillo, CJ. Madrid Navarro, T. Muñoz-Ruiz, D. Rodríguez-Martín, B. Oliver Martos, P. Serrano Castro, JJ. González-Rosa, P. Mir, F. Escamilla Sevilla (Granada, Spain)

Motor variability in isolated and probable REM sleep behaviour disorder using remote finger tapping

H. Chohan, S. Water, L. Pérez-Carbonell, G. Leschziner, T. Periñán, B. Huxford, S. Eriksson, J. Bestwick, A. Schrag, A. Noyce, C. Simonet (London, United Kingdom)

Multimodal Immune Biomarkers of Parkinson’s Disease Progression

A. Friend, K. Scott, A. Peattie, L. Spindler, T. Fryer, Y. Hong, C. Williams-Gray (Cambridge, United Kingdom)

Multiplexed Serum Biomarkers for Differentiating the Parkinson’s Disease Continuum and Disease Severity

MS. Kim, IH. Kwak, JK. Yu, H. Ma, K. Choi, J. Kim, H. Hwang, YE. Kim (Hwaseong, Republic of Korea)

Neuroinflammation and neurodegeneration biomarkers in Parkinson’s disease: integration of neuroimaging and fluid markers

L. Melgarejo Martinez, S. Enriquez, A. Lopez, D. Samaniego, M. Miret, A. Laguna, M. Martinez, C. Lorenzo, J. Hernandez (Barcelona, Spain)

Non-Rapid Eye Movement Sleep Neurophysiological Alterations in Lewy Body Disorders

J. Anderson, L. Churchill, A. Konuri, A. Ignatavicius, G. Cho, A. Lam, S. Naismith, R. Grunstein, S. Lewis, E. Matar (Camperdown, Australia)

Olfactory Dysfunction Across Neurodegenerative Disorders: A Prospective Cross-Sectional Comparison of Parkinson’s Disease, Alzheimer’s Disease and Idiopathic REM Sleep Behavior Disorder

J. Einhaus, E. Kara, H. Jergas, C. Schedlich-Teufer, G. Tamgüney, G. Fink, M. Sommerauer, ö. Onur, M. Barbe (Jülich, Germany)

Paired cerebrospinal fluid and serum analysis of irisin and associated LC3B levels in Parkinson’s disease and atypical Parkinsonism

S. Witte, C. van Riesen, M. Bähr, F. Maass (Göttingen, Germany)

Parkinson’s Disease Early Diagnostic and Prognostic Biomarkers Identified by Large-scale Plasma and Cerebrospinal Fluid Proteomic Profiling

XY. Li, YL. Tang, J. Wang (Shanghai, China)

PD Similarity Index: A Wearable Gait Biomarker Capturing the Continuum from iRBD to Parkinson Disease

S. Kim, J. Jung, P. Lee, S. Kang, M. Son, J. Jeon (Busan, Republic of Korea)

Peripheral Inflammatory Biomarkers as Predictive Indicator for Parkinson’s Disease: a Systematic Review and Meta-Analysis

H. Hussien, A. Hegazi, A. Elsaid (Dakahlia, Egypt)

Peripheral Inflammatory Markers and Clinical Correlations in Parkinson’s Disease Patients Carrying LRRK2 G2385R and R1628P Variants

HX. Ding, TS. Toh, NJ. Zulkefli, NS. Zulhaimi, AN. Khairul Anuar, JW. Hor, YW. Tay, IX. Kong, YC. Pang, R. Rajasuriar, SY. Lim, AH. Tan, LC. Lit (Kuala Lumpur, Malaysia)

Plasma Exosomal Cytokines as Longitudinal Biomarkers and Predictors of Parkinson’s Disease Progression

CT. Hong, CC. Chung (New Taipei, Taiwan)

Plasma Fibrinogen Associates with Dopaminergic Neurodegeneration Independent of Peripheral Inflammation in drug-naïve Parkinson’s Disease

T. Umehara, Y. Muraoka, Y. Nakayama, M. Mimori, M. Ozawa, T. Kitagawa, H. Matsuno, S. Omoto, R. Sengoku, Y. Iguchi (Tokyo, Japan)

Platelet Lipididomic and Alpha-Synuclein as Peripheral Biomarkers of Disease Progression and Risk in GBA1-Associated Parkinson’s Disease

G. Uras, S. Lucas Del-Pozo, V. Lentini, A. Pantaleo, D. Hughes, P. Caboni, C. Manis, A. Schapira (London, United Kingdom)

Predicting Dementia in Parkinson’s Disease Using Blood-Based Proteomics

R. Real, Y. Kordovska, O. Swann, A. Nodehi, Y. Ben-Shlomo, N. Williams, D. Grosset, J. Hardy, A. Heslegrave, H. Zetterberg, H. Morris (London, United Kingdom)

Probabilistic Mapping of Subthalamic Beta and Theta Subcircuits Reveals Segregated Connectivity and Deep Brain Stimulation Outcomes in Parkinson’s Disease

E. Schmehr, C. Schedlich-Teufer, J. Strelow, T. Schüller, T. Dembek, A. Horn, V. Visser-Vandewalle, G. Fink, J. Baldermann, M. Barbe (Cologne, Germany)

Quantitative Assessment of Rigidity in Parkinson’s Disease Using Wearable Inertial Sensors and Electromyography During Daily-Life Monitoring

C. Travassos Valdez, C. Marques Alves, F. Sanchez Cuesta, M. Filfil, C. Molina Carrillo, S. Fernandez Rojo, J. Romero Muñoz (Pozuelo de Alarcón, Madrid, Spain)

Quantitative Neurodegenerative Risk Modelling and Clinical Score Prediction Using Mixed Reality

J. Stępień, M. Baran, W. Szecówka, N. Bozetine, M. Dudek, J. Krzywdziak, M. żbik, J. Sikora, D. Hemmerling, M. Wójcik-Pędziwiatr (Kraków, Poland)

Real-Time Quaking-Induced Conversion Detection of Tear Fluid α-Synuclein as a Potential Biomarker for Parkinson’s Disease

A. Kakimoto, K. Satoh, T. Tsukahara-Kawamura, Y. Tsuboi (Nagasaki, Japan)

Real-World Turning Impairments in Fallers with Parkinson’s Disease

V. Shah, R. Baudier, C. Silva-Batista, A. Ragothaman, P. Carlson-Kuhta, J. Lapidus, F. Horak, M. Mancini (Portland, USA)

Reduced Glucocerebrosidase Activity Is Associated with Cognitive Decline in Severe GBA1-Associated Parkinson’s Disease

D. Macias-Garcia, P. Garcia-Sanz, S. Ojeda-Noda, L. Murillo-Hernández, L. Muñoz-Delgado, A. Adarmes-Gómez, S. Jesus, C. Perez-Calvo, M. San Eufrasio, AM. Castellano-Guerrero, AC. Luque-Ambrosiani, E. Ojeda-Lepe, M. Martín-Bórnez, R. Diaz-Belloso, S. García-Díaz, D. Buiza-Rueda, M. Bonilla-Toribio, R. Pineda-Sanchez, P. Gomez-Garre, P. Mir (Sevilla, Spain)

Reduced Whole-blood Energy Metabolism in Parkinson’s Disease.

Y. Mizutani, R. Ohdake, Y. Maeda, T. Maeda, R. Nagao, K. Kawabata, S. Shima, A. Ueda, M. Ito, H. Watanabe (Toyoake, Japan)

Retrospective Evaluation of microRNA-7-5p and Neuron-Derived α-Synuclein in Prodromal Parkinson’s Disease as Phenoconversion Biomarkers

C. Adams, S. Zadegan, K. Muthiah, P. Velammal, M. Jatty (Memphis, USA)

Risk stratification study of fluid biomarkers for alpha-synucleinopathy with dementia

R. Kamo, A. Okuzumi, H. Takeshige, N. Nishikawa, N. Hattori, T. Hatano (Bunkyo, Japan)

Seed Amplification Assay Is More Sensitive To Detecting α-Synuclein In Gut Biopsies Than Immunohistochemistry

B. Killinger, J. Duvernay, S. Choi, S. Pritzkow, M. Pinho, P. Engen, M. Shaikh, L. Zhang, C. Neumann, M. Villanueva, D. Sanchez-Bass, L. Dibenedetto, M. Abdel-Mohsen, S. Green, L. Lagorio, S. Luo, R. Voigt, A. Sharma, C. Goetz, A. Keshavarzian (Chicago, USA)

SEMG for Dyskinesia Detection in Parkinson’s Disease Using Machine Learning

E. Muñoz-Delcampo, C. Perez-Lopez, J. Solé-Casals, M. Grande-Gordon, I. Gonzalo-Asenjo, L. Márquez-López, M. Montesinos-Terceño, P. Rodríguez-Sánchez (Cornellà de Llobregat, Spain)

Sensitivity of AI-Derived Video-Based Digital Biomarkers to Motor Progression in Parkinson’s Disease

T. Zarrat Ehsan, M. Tangermann, B. Bloem, L. Evers (Nijmegen, Netherlands)

Serum Based biomarkers in Parkinson’s disease with and without cognitive deficits.

R. Bhavani, S. Choudhury, NC. Krithika, K. Krishnakumari, V. Holla, P. Pal, N. Kamble, S. Hegde, R. Yadav, P. Alladi (Bangalore, India)

Serum Nutritional Biomarkers Associated with Isolated REM Sleep Behavior Disorder and α-synucleinopathy Phenoconversion

H. Zhang, Y. Zang, T. Wang, Y. Li, Y. Yuan, Y. Cai, C. Piu, W. Mao (Beijing, China)

Smartwach Actigraphy for Detection of REM Sleep Behavior Disorder: The dBM-DEV Study

N. Schnalke, T. Feige, J. Zaras, C. Chatzichristos, F. Wang, M. de Vos, I. Gerasimou, A. Moustaklis, N. Del Campo, M. Fabbri, R. Debs, M. Almarcha-Menargues, M. Kurtis, O. Sanchez-Solino, D. Matzakou-Karvouniari, A. Mioglou, C. Sotirakis, L. Hadjileontiadis, S. Hadjidimitriou, B. Falkenburger (Dresden, Germany)

smSAA: developing a quantitative seed amplification assay with single molecule spectroscopy

E. Sierecki, P. Manandhar, J. Rukhaya, Y. Graves, Y. Gambin (Sydney, Australia)

Speech Impairment Severity and Motor Symptom Lateralisation in Advanced Parkinson’s Disease

T. Tienkamp, T. Thies, P. Schumacher, D. Mücke, M. Barbe (Cologne, Germany)

Standardised Home-Based Walk Tests Can Capture Gait Differences in Parkinson’s Disease Using Wearable Sensors

C. Sotirakis, N. Conway, J. Ren, M. Dockendorf, O. Patil, S. Lee, J. Fitzgerald, C. Antoniades (University of Oxford, United Kingdom)

Subthalamic Beta Sub-band Composition and Gamma Dynamics Across Medication and Stimulation States in Parkinson’s Disease

Q. Li, K. Wang, X. Jia, J. Li, X. Zhang, Y. Shan, A. Kühn, M. Tuersun, Y. Zhang, B. Niu, N. Li, J. Wu, G. Zhao, Y. Zhang (Beijing, China)

Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disorders

C. Simonet, J. Yin, L. Chahine, D. Weintraub, K. Chatterjee, C. Caspell-Garcia, D-E. Lafontant, A. Noyce, T. Simuni (London, United Kingdom)

The enteric footprint of de novo parkinson’s disease cohort: constipation, inflammation, and nulisa biomarker profiling.

S. Enriquez Calzada, M. Miret Milian, L. Melgarejo, M. Arrué, A. López, S. Belmonte, M. Martinez-Vicente, J. Hernandez-Vara, A. Laguna (Barcelona, Spain)

The Syn-Q Study: Quantification of phosphorylated alpha-synuclein in patients with Parkinson’s disease and REM sleep behavior disorder

R. Freeman, T. Levine, J. Parent, S. Marcotte, B. Bellaire, M. Duval, C. Gibbons (Boston, USA)

Title: Association of Neurofilament Light Chain and Peripheral Inflammatory Biomarkers with Clinical Progression in Parkinson’s Disease

D. Daminov, A. Xamidov, F. Saidvaliev (Tashkent, Uzbekistan)

Tongue Shape Complexity in Cantonese Parkinsonian Speech

C. Wang, M. Wong, B. Wang (Kowloon, Hong Kong)

Translational Target Engagement of HER-096 Demonstrates Concordant Proteostasis and Mitochondrial Modulation in Preclinical Models and Patients with Parkinson’s Disease

K. Holmström, A. Ludwig, N. Kulesskaya, A. Domanska, K. Jääskeläinen, C. Videbaek, H. Huttunen (Espoo, Finland)

Uncovering Parkinson Disease Progression Biomarkers with Plasma Proteomics and Functional Genomics

C. Jeong, JS. Kim, S. Kim, H. Kim, S. Lee, KB. Jo, SH. Ha, W. Luo, KA. Woo, I. Shlaifer, JH. Shin, T. Durcan, KJ. Yoon, DK. Kim, HJ. Kim (Seoul, Republic of Korea)

Underestimation of Nighttime Sleep Symptoms in Isolated RBD is Associated with Increased Risk of Phenoconversion to Synucleinopathy: A North American Prodromal Synucleinopathy Consortium Study

J. Ha, D. Bliwise, H. Dela Cruz, C. Xiong, T. Ferman, K. Kantarci, V. Lowe, S. Criswell, E. ST. Louis, D. Huddleston, A. Avidan, Y. Ju, M. Lim, M. Miglis, R. Postuma, A. Videnovic, B. Boeve, M. Howell, L. Trotti (Atlanta, USA)

Unraveling Kinase-Phosphatase Dysregulation in Parkinson’s disease Peripheral Blood Mononuclear Cells Through Targeted Transcript Analysis

E. Basu, R. Banerjee, B. Biswas, S. Mondal, J. Rungta, S. Sengupta, J. Ganguly, D. Dutta, S. Mukherjee, P. Basu, S. Choudhury, H. Kumar (Kolkata, India)

Untangling the Web of Fall Risk in Parkinson’s Disease Through Machine Learning

M. Bradley, C. O'Keeffe, J. Inocentes, A. Gill, C. Espinoza Vinces, F. Ruggieri, R. Reilly, C. Fearon (Dublin, Ireland)

Upper Limb Coordination During Walking is Associated with Clinical Severity in Parkinson’s Disease

P. Sharma, C. Sotirakis, P. Barmpas, N. Conway, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

Urine and Plasma Bis(monoacylglycero)phosphate (BMP) in Asian LRRK2 p.G2385R and p.R1628P Variant Carriers with Parkinson’s Disease

AN. Khairul Anuar, SY. Lim, TS. Toh, CCY. Lew, JW. Hor, YW. Tay, A. Ahmad-Annuar, L. Li, F. Hsieh, LC. Lit, AH. Tan (Kuala Lumpur, Malaysia)

Urine-derived neuronal extracellular vesicle α-synuclein seed amplification assay for synucleinopathies: a non-invasive biomarker study

HBT. Tran, TA. Nguyen, HJ. Choi, HD. Nguyen, IH. Kwak, DG. Ko, JK. Yu, SJ. Song, JH. Lim, YE. Kim (Chuncheon, Republic of Korea)

Vitamin D Status and Levodopa Responsiveness in Parkinson Disease and Association With Gastrointestinal Symptoms

G. Saidakhmetova, ZH. Myrzayev, G. Mussagaliyeva, D. Bagautdinov, CH. Shashkin (Almaty, Kazakhstan)

Volatile Organic Compound Signatures Differentiate Parkinson Disease from Parkinson Disease Mimic Syndromes and Controls

A. Dixon, L. Sun, P. Jones, B. Daud Shah, A. Rajput, H. Zhang, E. Noyes (Saskatoon, Canada)

Wearable assessment of levodopa-entacapone-carbidopa intestinal gel treatment characteristics at home: Pilot Protocol

J. Gerstl, H. Widner (Lund, Sweden)

Wearable Gait Metrics as Potential Digital Biomarkers in GBA1 Non-Manifesting Carriers

N. Loefflad, F. Fraser, C. Sotirakis, M. Toffoli, C. Antoniades, AHV. Schapira (London, United Kingdom)

Wearable-Derived Gait Biomarkers Predict Disease Severity and Quality of Life in Parkinson’s Disease: A Machine Learning and Mediation Analysis

J. Jiang, W. Wang, W. Wei, L. Li, O. Ou, Z. Zhang, H. Hou, Y. Yang, X. Xiao, L. Lin, L. Liu, S. Shang (chengdu, China)

Why Context Matters: The Influence of Medication and Environment on Real-World Gait in People with Parkinson’s Disease

C. Lang, M. Galeon, C. Kirk, E. Packer, N. Ireson, V. Lanfranchi, L. Alcock, L. Rochester, A. Yarnall, S. Del Din*, D. Ravi* (Zurich, Switzerland)

α-Synuclein biomarkers in prodromal synucleinopathies: a systematic review and meta-analysis.

S. Virameteekul, S. Lim, R. Postuma, E. de Pablo-Fernández, A. Noyce (Bangkok, Thailand)

« View all sessions from the 2026 International Congress.

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley